Upper Prosthesis is the fastest-growing type line in the orthopedic prosthetics market, compounding at 8.13% a year, and the ground it gains is taken from Lower Prosthesis. Its share of revenue climbs from 32% to 35%, while the larger line beside it gives up share across the forecast period.
Market Size and Why Upper Prosthesis Outruns It
The global orthopedic prosthetics market was valued at USD 4350 million in 2025. It is projected to grow from USD 4628 million in 2026 to USD 7993 million by 2034, a compound annual growth rate of 7.07% during the forecast period. Contrive Datum Insights reports these figures in its study of the market, which spans type, application, technology, material and end user.
Upper Prosthesis grows faster than that overall rate, and its value roughly doubles, from USD 1392 million to USD 2798 million. The study traces the pull to one cause above the rest: rising diabetes-related and trauma-driven amputation and joint degeneration incidence, which it rates as the largest single contributor to growth, with a high impact. The type lines most exposed to that demand move first, and Upper Prosthesis is one of them.
Other segments show the same direction of travel. Myoelectric & Robotic-Assisted Prosthetics grows at 10.68% against a Conventional Prosthetics base that holds 72% of 2025 revenue. In materials, Carbon Fiber & Composite grows fastest at 11.07%, while Metal & Alloys still leads with 40%. Among end users, Rehabilitation Centers grow at 8.67%, ahead of Prosthetic & Orthotic Clinics, which lead on size with 45%.
Regions, and the Weight of the Larger Segment
North America leads with 38% of 2025 revenue, worth USD 1653 million, and reaches USD 2717 million by 2034. The United States is the largest single country market at USD 1438 million in 2025, or 33.06% of global revenue. Asia Pacific gains ground steadily, moving from 22% of revenue in 2025 to 27% in 2034 as its revenue expands from USD 957 million to USD 2158 million. Middle East and Africa stays the smallest region, at 6% in 2025 and 6.5% by 2034.
Buyers differ by product. Orthopedic surgeons and hospital procurement teams source joint implants, while prosthetists, rehabilitation clinics and amputee patients source external limbs. Insurers and public health payers influence access to both.
Lower Prosthesis is the counterweight. It holds 68% of 2025 revenue, worth USD 2958 million, and it is still the largest line in 2034 at 65%. Its growth rate of 6.53% sits below the market's 7.07%, which means the biggest block of revenue is the one pulling the average down. The study also models scenarios for the headline total: a bear case of USD 7194 million and a bull case of USD 8792 million by 2034, against the USD 7993 million base case.
The report is delivered as a PDF, and a free sample is available on request.